While this finding has important implications for the development of failed anti-androgen treatment, Brooke et al. [46] found that ARA70N enhances agonist activity of hydroxyflutamide only with human prostate cancer LNCaP cell AR, which contains a point mutation (T877A) within the LBD. This evidence concerns the gene AR and prostate carcinoma.